Swiss Insurance Stock News

SWX:GALE
SWX:GALEHealthcare

Galenica (SWX:GALE) Just Gave Investors Something To Think About

Galenica (SWX:GALE) is back in focus after its half year 2026 results showed higher sales and revenue alongside lower net income, while the company reaffirmed its 2026 guidance for net sales and EBIT growth. See our latest analysis for Galenica. Galenica’s recent half year results and confirmed 2026 guidance come after a share price that is down 17.6% year to date to CHF81.1, while the 5 year total shareholder return of 31.1% points to a stronger longer term picture. Short term share price...
SWX:TKBP
SWX:TKBPBanks

Thurgauer Kantonalbank (SWX:TKBP) Stock Premium Meets Slower Profit Conversion

Thurgauer Kantonalbank stock has gone almost nowhere over the past week, yet the latest earnings quietly pushed the story a little further ahead. Net income over the last twelve months sits at CHF 162.967m while the P/E multiple is about 20.2x, above the European banks average. The real tug of war today is between that premium pricing and a net profit margin of 36.8% that slightly trails last year. The question for investors is whether this modest margin squeeze justifies any strong emotional...
SWX:GLKBN
SWX:GLKBNBanks

Glarner Kantonalbank (SWX:GLKBN) Stock Can Firmer Margins Sustain Optimism

Glarner Kantonalbank stock has been grinding higher in recent weeks, with a 3‑month gain in double digits. Today the focus sits squarely on what those earnings are doing to profitability. The headline is margins. Net profit margin for the last twelve months stands at 25%, compared with 22.7% a year earlier, which helps explain why the stock screens on investors’ radars even with a P/E of 13.4x. Short‑term traders may fixate on today’s price move. Longer term investors will likely pay more...
SWX:GALD
SWX:GALDPharmaceuticals

Galderma Group (SWX:GALD) Wins EU Nod For Restylane Shaype, Is It Fully Priced?

Restylane Shaype launch puts Galderma Group in focus Galderma Group (SWX:GALD) has drawn fresh investor attention after securing European Union approval for Restylane Shaype, a hyaluronic acid gel designed specifically for minimally invasive chin shaping and augmentation. See our latest analysis for Galderma Group. The Restylane Shaype approval lands at a time when Galderma Group’s share price has eased in the very short term, with the 1 day and 7 day share price returns declining 3.11% and...
SWX:SREN
SWX:SRENInsurance

Swiss Re (SWX:SREN), Why Is Its Latest Update Drawing Attention?

Swiss Re (SWX:SREN) is drawing fresh attention after its H1 2026 results, with net income of US$2.831b and basic earnings per share of US$9.57 for the six months to June 30. See our latest analysis for Swiss Re. Swiss Re's share price has climbed over the past quarter, with a 90 day share price return of 14.82% and a year to date share price return of 7.15%. The 3 year total shareholder return of 93.41% highlights how long term holders have been rewarded, as recent earnings keep interest in...
SWX:KOMN
SWX:KOMNMachinery

Komax Holding (SWX:KOMN) Stock Price Trails Losses Despite Deep Value Gap

Komax Holding shares closed at CHF78.70 on Friday, only modestly higher over the past week and month, which suggests investors came into these results cautiously optimistic but not euphoric. The earnings headline is simple and uncomfortable. The wiring automation specialist is still loss making, with a basic earnings per share loss of CHF0.96 in the first half and trailing twelve month losses that remain in the mid single digit millions of francs. The key issue now is valuation. The stock...
SWX:ALC
SWX:ALCMedical Equipment

Is Alcon (SWX:ALC) Below Fair Value On Mixed Earnings And RxSight News?

Alcon (SWX:ALC) is back in focus after its second quarter 2026 earnings report. The results showed higher sales and revenue but a much lower net income figure, giving investors mixed signals to digest. See our latest analysis for Alcon. The recent earnings announcement, maintained 2026 net sales growth guidance, and the RxSight collaboration have come alongside a 90 day share price return of 17.97%, although the 1 year total shareholder return is down 13.93%. If this mix of earnings and...
SWX:TEMN
SWX:TEMNSoftware

Temenos (SWX:TEMN) Approves A CHF100 Million Buyback, Is The Upside Already Priced In?

Temenos (SWX:TEMN) has drawn fresh attention after its Board of Directors approved a share repurchase program of up to CHF 100 million, with the buyback running until February 26, 2027. See our latest analysis for Temenos. The buyback news comes after a mixed period for Temenos, with the share price at CHF73.25 and a 7 day share price return of 5.40% signalling short term momentum. The year to date share price return is down 10.12% and the 5 year total shareholder return is down 43.34%. If...
SWX:ARYN
SWX:ARYNFood

ARYZTA (SWX:ARYN) Just Gave Investors Something To Reassess

ARYZTA (SWX:ARYN) has come into focus after reporting half year 2026 results that showed slightly lower sales and earnings. Investors are weighing what these updated figures mean for the stock. See our latest analysis for ARYZTA. ARYZTA's recent half year 2026 update comes after a tougher stretch for the stock, with the share price at CHF45.25 and the 30 day share price return down 18.32%. The 1 year total shareholder return is down 39.22%, which points to fading momentum as investors...
SWX:ADEN
SWX:ADENProfessional Services

Adecco Group (SWX:ADEN) Wins 2026 HR Tech Award For AI Career Platform

Adecco Group (SWX:ADEN) unit LHH Career Studio has received the Career Development Innovation Award at the 2026 HR Tech Breakthrough Awards. The award recognizes LHH Career Studio's AI powered career transition platform for its role in digital talent solutions. The recognition comes as Adecco Group continues to focus on AI and digital transformation across its services. Readers looking for more ideas in AI focused talent and HR technology can explore 130 AI small caps. SWX:ADEN Earnings &...
SWX:SQN
SWX:SQNCapital Markets

Swissquote (SWX:SQN) Stock Price Slides As Margin Strength Meets Growth Doubts

Swissquote Group Holding heads into the post earnings session with a stock that has drifted lower in recent weeks, despite a profit story that still looks powerful. The market has marked the share price down over the past month, yet trailing net income and earnings per share point to a business that continues to convert revenue into profit at a high level. The heart of this release is margin resilience. A trailing net profit margin above 40% indicates that Swissquote is still keeping a very...
SWX:NESN
SWX:NESNFood

Nestlé (SWX:NESN) Climbed, So What Is Driving Attention Now?

Nestlé stock in focus after renewed growth narrative Nestlé (SWX:NESN) is back on investors’ radar after recent coverage highlighted its profitability trends and focus on health science nutrition, pet care, premium coffee and related protein segments linked to growing whey protein demand. See our latest analysis for Nestlé. Nestlé’s share price has climbed 6.06% year to date to CHF81.07, while a 17.08% total shareholder return over the past year suggests that investors are gradually warming...
SWX:AMS
SWX:AMSSemiconductor

ams-OSRAM (SWX:AMS) Shares Jumped, What Is Behind The Move?

ams-OSRAM (SWX:AMS) shares are in focus after the company reported Q2 2026 results showing higher sales but a larger net loss, alongside fresh Q3 guidance and a softer full year revenue outlook. See our latest analysis for ams-OSRAM. The Q2 update and new Q3 guidance follow a strong rebound in ams-OSRAM's share price, with a year-to-date share price return of 122.75% and a 1-year total shareholder return of 81.21%, although the 5-year total shareholder return is down 79.53%. If this earnings...
SWX:ALC
SWX:ALCMedical Equipment

3 European Stocks Estimated To Be Up To 49.8% Below Intrinsic Value

The European stock market has recently shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.70% amid firmer risk appetite and robust earnings, despite a volatile geopolitical environment. As investors navigate these conditions, identifying undervalued stocks becomes crucial for capitalizing on potential opportunities within this fluctuating landscape.
SWX:ALC
SWX:ALCMedical Equipment

Alcon (SWX:ALC) Stock Grapples With Profit Reset Despite Stronger Sales

Alcon stock closed at CHF61.06 on 11 August after a strong run over the past quarter. Yet the real story now sits in the income statement. Q2 sales landed at about US$2.8b with 7% growth, but the headline tension for investors is profits. Trailing 12 month net profit margin is 5.9% compared with 10.7% a year earlier, held back by a US$453m one off loss that still hangs over reported earnings. For anyone thinking beyond this quarter, the key question is how quickly those margins can rebuild as...
SWX:TECN
SWX:TECNLife Sciences

Tecan Group (SWX:TECN) Stock Faces Margin Squeeze Despite Rewired Progress

Tecan Group stock closed at CHF181.2 on the day of its half year 2026 report, after a choppy few months that left the shares down over the past week but still well ahead over ninety days. The headline is not the top line. The real story is a margin picture under pressure, with gross margin slipping while adjusted EBITDA margin held at 15.1% and cash generation came in soft at CHF17m. Short term traders are reacting to squeezed profitability. Long term holders now have to judge whether the...
SWX:ADEN
SWX:ADENProfessional Services

Adecco Group (SWX:ADEN) Reported Higher Sales And Lower Net Income, Is It Above Fair Value?

Adecco Group (SWX:ADEN) is in focus after reporting half year 2026 results that showed slightly higher sales but a small decline in net income, raising fresh questions about earnings quality and stock valuation. See our latest analysis for Adecco Group. Adecco Group's latest earnings update arrives after a strong run in the share price. The 30 day share price return is 35.98% and the 90 day share price return is 54.89%. However, the 1 year total shareholder return is still down 5.37%, which...
SWX:ARYN
SWX:ARYNFood

ARYZTA (SWX:ARYN) Stock Faces Debt Questions After Flat First Half

ARYZTA stock came into today on the back foot, with the share price down about 18% over the past three months. However, the latest earnings headline is less about the income statement and more about the balance sheet. The company still carries a high level of debt, which now sits against a business generating trailing net income of just over €100m and a net margin under 5%. For you as an investor, the key question after this set of numbers is simple: does the current P/E discount and heavy...
SWX:LOGN
SWX:LOGNTech

Should Logitech’s Q1 Beat, Buybacks and Streamlabs Upgrade Require Action From Logitech (SWX:LOGN) Investors?

In late July 2026, Logitech International reported first-quarter sales of US$1,227.23 million and net income of US$235.7 million, while issuing second-quarter fiscal 2027 sales guidance of US$1,185 million to US$1,220 million and completing a US$100.78 million buyback of 926,000 shares. Logitech’s Streamlabs unit also introduced Network Boost for Streamlabs Ultra, turning everyday smartphones into bonded Wi‑Fi and cellular links to improve mobile stream reliability and expand higher-margin...
SWX:CICN
SWX:CICNElectronic

European Value Stocks Estimated Below Intrinsic Worth In August 2026

European markets have recently shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.70%, supported by firm risk appetite and stable earnings despite ongoing geopolitical volatility. As investors navigate these conditions, identifying stocks that are potentially undervalued compared to their intrinsic worth can offer opportunities for those looking to capitalize on market inefficiencies.
SWX:CLN
SWX:CLNChemicals

Clariant (SWX:CLN) Lifts Profitability, Is The Upside Already Priced In?

Clariant (SWX:CLN) has drawn fresh attention after reporting half year 2026 earnings that combined lower sales with higher profitability, including stronger net income and earnings per share from continuing operations. See our latest analysis for Clariant. The latest half year earnings and the favorable court ruling at the end of July appear to have supported sentiment around Clariant, with the CHF10.10 share price reflecting a 35.39% 1 month share price return and a 41.95% year to date share...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN) FDA Approval Puts Pluvicto Value Story Back In Focus

Novartis (SWX:NOVN) is back in focus after the US FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, materially widening the therapy’s eligible patient pool. See our latest analysis for Novartis. Against this backdrop, Novartis shares trade at CHF125.98, with a 90 day share price return of 10.8% and a year to date share price return of 16.11%. The 1 year total shareholder return of 38.01% points to...
SWX:INRN
SWX:INRNMachinery

Is Interroll Holding (SWX:INRN) Undervalued On Mixed Half Year Earnings?

Half year earnings highlight mixed trends for Interroll Holding stock Interroll Holding (SWX:INRN) reported half year 2026 earnings with sales of CHF 269.93 million compared with CHF 247.65 million a year earlier, while net income moved to CHF 19.75 million from CHF 21.22 million. See our latest analysis for Interroll Holding. Interroll Holding's recent earnings update comes after a period where the share price has risen about 10.17% over the past month but is still down 36.59% year to date,...